BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...said Patrick Shea has joined as SVP of commercial. He was chief commercial officer of Egalet...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...company Cerecor Inc. (NASDAQ:CERC) hired Jeff Wilkins as chief development officer. He was CMO at Zyla Life Sciences...
BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...aren’t on that formulary, and other more recently approved therapies haven’t fared well. For example, Egalet...
...its higher-priced opioids. Egalet filed for bankruptcy in 2018. The company re-launched in 2019 as Zyla Life Sciences...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...B.V. hired Stanley Musial as CFO and CBO. Musial served as CFO of EryDel S.p.A., Egalet...
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

...who received Caldolor as compared to those receiving placebo (47 mg and 56 mg, respectively)." Egalet...
BioCentury | Dec 22, 2017
Clinical News

FDA tentatively approves abuse deterrent claim for Egalet's Arymo ER

...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet...
...granted another company expires on Oct. 2, 2018. Arymo ER uses Egalet's Guardian abuse-deterrent technology. Egalet...
...Pa. Product: Arymo ER morphine sulfate extended-release (formerly Egalet-001) Business: Neurology Jaime De Leon Arymo ER morphine sulfate extended-release Egalet...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:FOLD) 7/12/17 $258.8 $2,009.5 $2,481.7 23% Arena Pharmaceuticals Inc. (NASDAQ:ARNA) 7/12/17 $172.5 $935.1 $1,000.1 7% Egalet...
BioCentury | Jun 23, 2017
Clinical News

Egalet receives CRL for 10 and 15 mg doses of pain drug Oxaydo

...Aversion abuse-deterrent technology from Acura Pharmaceuticals Inc. (NASDAQ:ACUR) and is designed to discourage intranasal abuse. Egalet...
...a 2015 deal (see BioCentury, Jan. 12, 2015 ). Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Egalet...
...NASDAQ:EGLT), Wayne, Pa. Product: Oxaydo oxycodone (Aversion) (formerly Acurox , Oxecta) Business: Neurology Julian Zhu Aversion Oxaydo Acura Pharmaceuticals Inc. Egalet...
BioCentury | Apr 7, 2017
Finance

Fade to black

...undergone autologous stem cell transplantation (ASCT) Celltrion Inc. (KOSDAQ:068270) EC approves the biosimilar Truxima rituximab Egalet...
BioCentury | Jan 20, 2017
Financial News

Egalet completes private placement of senior notes

...On Jan. 18, pain and drug delivery company Egalet Corp. (NASDAQ:EGLT) raised $40 million in the...
...Investors also have a right to receive a 1.5% royalty payment on net sales of Egalet’s...
...approved this month. Morgan Stanley was the placement agent. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Alex Himes Arymo ER Egalet...
Items per page:
1 - 10 of 105
BioCentury | Jul 22, 2020
Management Tracks

Meeker expands role at Rhythm; plus Biogen, Kronos, Citryll, Akcea, ImmunoGen, Circle, Antares and more

...said Patrick Shea has joined as SVP of commercial. He was chief commercial officer of Egalet...
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...company Cerecor Inc. (NASDAQ:CERC) hired Jeff Wilkins as chief development officer. He was CMO at Zyla Life Sciences...
BioCentury | Feb 1, 2020
Company News

Any chance left for safer opioids?

...aren’t on that formulary, and other more recently approved therapies haven’t fared well. For example, Egalet...
...its higher-priced opioids. Egalet filed for bankruptcy in 2018. The company re-launched in 2019 as Zyla Life Sciences...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...B.V. hired Stanley Musial as CFO and CBO. Musial served as CFO of EryDel S.p.A., Egalet...
BioCentury | Dec 8, 2018
Regulation

Path to opioid-free pain relief

...who received Caldolor as compared to those receiving placebo (47 mg and 56 mg, respectively)." Egalet...
BioCentury | Dec 22, 2017
Clinical News

FDA tentatively approves abuse deterrent claim for Egalet's Arymo ER

...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet...
...granted another company expires on Oct. 2, 2018. Arymo ER uses Egalet's Guardian abuse-deterrent technology. Egalet...
...Pa. Product: Arymo ER morphine sulfate extended-release (formerly Egalet-001) Business: Neurology Jaime De Leon Arymo ER morphine sulfate extended-release Egalet...
BioCentury | Oct 6, 2017
Finance

High as a Kite

...NASDAQ:FOLD) 7/12/17 $258.8 $2,009.5 $2,481.7 23% Arena Pharmaceuticals Inc. (NASDAQ:ARNA) 7/12/17 $172.5 $935.1 $1,000.1 7% Egalet...
BioCentury | Jun 23, 2017
Clinical News

Egalet receives CRL for 10 and 15 mg doses of pain drug Oxaydo

...Aversion abuse-deterrent technology from Acura Pharmaceuticals Inc. (NASDAQ:ACUR) and is designed to discourage intranasal abuse. Egalet...
...a 2015 deal (see BioCentury, Jan. 12, 2015 ). Acura Pharmaceuticals Inc. (NASDAQ:ACUR), Palatine, Ill. Egalet...
...NASDAQ:EGLT), Wayne, Pa. Product: Oxaydo oxycodone (Aversion) (formerly Acurox , Oxecta) Business: Neurology Julian Zhu Aversion Oxaydo Acura Pharmaceuticals Inc. Egalet...
BioCentury | Apr 7, 2017
Finance

Fade to black

...undergone autologous stem cell transplantation (ASCT) Celltrion Inc. (KOSDAQ:068270) EC approves the biosimilar Truxima rituximab Egalet...
BioCentury | Jan 20, 2017
Financial News

Egalet completes private placement of senior notes

...On Jan. 18, pain and drug delivery company Egalet Corp. (NASDAQ:EGLT) raised $40 million in the...
...Investors also have a right to receive a 1.5% royalty payment on net sales of Egalet’s...
...approved this month. Morgan Stanley was the placement agent. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa. Alex Himes Arymo ER Egalet...
Items per page:
1 - 10 of 105